Phase II/III Adaptive Multicenter Clinical Study of XB20-01 for colorectal cancer
Latest Information Update: 06 May 2021
At a glance
- Drugs Vilamakitug (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 06 May 2021 New trial record
- 03 May 2021 According to XBiotech media release, French National Cancer Institute and XBiotech Join forces to conduct this trial
- 03 May 2021 According to XBiotech media release, Dr. Francois Ghiringhelli M.D. Ph.D, is lead investigator of this trial who designed the study which features an innovative interim analysis to assess improvement in overall survival. If patients receiving XB20-01 have a predetermined improvement in survival compared to the placebo treated group, the randomized study will be expanded to enroll a phase III portion with overall survival as the primary outcome.